iRegene
Latest round
- Series C
Last raised
- Jul 2026
Total raised
- $99M
Investors
- 21
About iRegene
, trading as iRegene, is a biotechnology company that focuses on the development of small chemical molecules to induce functional cell regeneration drugs. The company has established bases in Wuhan, Suzhou, China, as well as in Danmark, Singapore and Australia. In 2019, the company completed pilot scale production of NouvNeu001, a pipeline for treating Parkinson's disease. iRegene focuses on the development of small chemical molecules to induce functional cell regeneration drugs to cure Parkinson’s disease and blindness., that are powered by AI (Artificial Intelligence) and deep learning the company has developed multiple pipeline products for the treatment of Parkinson’s Disease, Multiple System Atrophy (MSA-P), Retinal Degenerative Diseases and Ischemic Stroke. The company generates revenue by developing new generation of chemically induced cell therapy products.
Who invested in iRegene
21 investors across 8 rounds
See all investors in iRegene
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series C
Jul 2, 2026
Amount
$38M
Investors
Series C
Jun 1, 2026
Amount
$31M
Investors
Series C
Mar 18, 2026
Amount
Undisclosed
Investors
Series B
Sep 4, 2025
Amount
Undisclosed
Investors
Series B
Apr 11, 2025
Amount
Undisclosed
Investors
Series B
Oct 14, 2024
Amount
$14M
Investors
Series A
Aug 11, 2021
Amount
$15M
Investors
Angel
Jan 1, 2019
Amount
Undisclosed
Investors
Questions about iRegene
Who invested in iRegene?
iRegene has 21 investors on record across 8 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has iRegene raised?
iRegene has raised 8 venture rounds. Sign up free to see how much each round raised and the total.
When did iRegene last raise money?
iRegene's most recent round on record is a Series C, in Jul 2026.
What does iRegene do?
, trading as iRegene, is a biotechnology company that focuses on the development of small chemical molecules to induce functional cell regeneration drugs.
Where is iRegene headquartered?
iRegene is headquartered in Chengdu, China.
Which VCs invest in companies like iRegene?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at iRegene's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like iRegene? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.